Kleiner Perkins — 2020 Investments
7 investments dated 2020 · listed companies and verified rows first · show all
South San Francisco, US
Board seatBeth Seidenberg· per SEC Form D · $70.7M raise · filed Feb 2021
Co-investorsSofinnova VenturesAbingworth
Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.
BiotechHealthtechMedical DevicesSouth San Francisco, US
James Ahlers(Executive Officer)Kenneth Drazan(Executive Officer, Director)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)Ken Drazan(Founder)
BoardValentin Barsan(Director)
Board seatBrook ByersBeth Seidenberg· per SEC Form D
Co-investorsARCH Venture PartnersHitachi VenturesOUP (Osage University Partners)SoftBank Vision FundWestlake Village BioPartners
San Francisco, US
Justin Santamaria(Executive Officer, Director)Rishi Mandal(Executive Officer, Director)
BoardYoon Chang(Director)
Board seatMamoon Hamid· per SEC Form D · $23.8M raise · filed Nov 2020
Walnut, US
Tiger Shen(Executive Officer, Director)Roberto Ortiz(Executive Officer, Director)Jerry Shen(Executive Officer, Director)
Board seatIlya Fushman· per SEC Form D · $12.2M raise · filed Nov 2020
San Francisco, US
PARKER CONRAD(Executive Officer, Director)Prasanna Sankaranarayanan(Executive Officer, Director)
Board seatMamoon Hamid· per SEC Form D · $145.3M raise · filed Aug 2020
Co-investorsFounders Fund
EnergyKing Of Prussia, US
Tim Brown(Executive Officer)Michael Hamilton(Executive Officer, Director)Jennifer Miller(Executive Officer)Kamal Gunsagar(Director)Bruce Wobeck(Executive Officer)Ajit Nazre(Director)
Board seatJohn Doerr· per SEC Form D · $48.6M raise · filed Apr 2020
Opstrace is an open source observability platform built on Cortex and Loki that runs in a user's own cloud account for metrics, logs, and alert management.
Cloud ComputingData & InfrastructureDeveloper ToolsSan Francisco, US
Sebastien Pahl(Executive Officer, Director)Mathew Appelman(Director)
BoardBucky Moore(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.